Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 123

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 123
---
Us is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates.As of March 31, 2025, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $17.2 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.2013 Employee Stock Purchase PlanIn June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 52,092 and 52,514 shares of common stock during the three months ended March 31, 2025 and 2024, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity 

13

to purchase up to an aggregate of 2,363,636 shares of our common stock. As of March 31, 2025, we had 1,531,142 shares of common stock available for future issuance under the 2013 ESPP.Stock-based compensation expenseStock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:Three Months EndedMarch 31,(In thousands)20252024Stock options$4,400 $4,071 Restricted stock units6,684 4,966 Employee stock purchase plan275 197 Total stock-based compensation expense$11,359 $9,234 Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:Three Months EndedMarch 31,(In thousands)20252024Research and development expense$4,604 $3,775 Selling, general and administrative expense6,755 5,459 Total stock-based compensation expense$11,359 $9,234 

10. Loss per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs and PSUs for which the performance and market vesting conditions